SomaLogic Expands Agreement With Novo Nordisk To 2025, Will Expand Its Use Of The SomaScan Proteomics Platform In Drug R&D Novo Nordisk Will Also Use SomaLogic's SomaSignal Tests For Investigations Into Cardiometabolic And Other Diseases
Portfolio Pulse from Happy Mohamed
SomaLogic has extended its collaborative agreement with Novo Nordisk until the end of 2025. As part of the agreement, Novo Nordisk will expand its use of the SomaScan proteomics platform in drug research and development, and will also use SomaLogic's SomaSignal tests for investigations into cardiometabolic and other diseases.
September 05, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novo Nordisk will expand its use of SomaLogic's proteomics platform and tests, potentially accelerating its drug R&D.
The extended agreement with SomaLogic allows Novo Nordisk to expand its use of the SomaScan platform and SomaSignal tests, which could potentially accelerate its drug research and development efforts. This could lead to positive investor sentiment and a potential increase in stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
SomaLogic extends its agreement with Novo Nordisk, securing a key partnership and potential revenue source until 2025.
The extension of the agreement with Novo Nordisk secures a key partnership and potential revenue source for SomaLogic until 2025. This could lead to positive investor sentiment and a potential increase in stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80